This meeting will represent a collaboration among academic researchers, clinical researchers, pharmaceutical and biotechnology companies, regulatory and health agencies, patient organizations, payors and venture capital/private equity concerns to address the need for effective therapies for rare diseases.
There will be three tracks offered:
- For Researchers, Drug and Device Companies
- For Patient Advocates and Patient Organizations
- For Investors
It is hosted by the National Organization for Rare Disorders (NORD) and the Drug Information Association (DIA). Additional support comes from the Food and Drug Administration (FDA), National Institutes of Health (NIH), European Rare Diseases Organization (EURORDIS) and Duke University School of Medicine.
Go to the website for more information about the program and registration. To apply for a press pass, contact Joe Krasowski: Joe.Krasowski@diahome.org.